Operates hospitals in China, Australia, and the Philippines. Develops and manages eldercare facilities, including nursing homes and service apartments. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (3% a year). Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.4× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 83% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $215.4M a year. A small number, but proof the product has real buyers.
A loss of $3.4M against $215.4M in annual sales.
The stock sits at $0.08. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.